Formulation of sustained - release ketorolac tromethamine pellets

Pharmaceutical Technology

Volumn 32, Issue 12, 2008, Pages 58-61

  Etman, Mohamed ^a   Nada, Hala ^b   Nada, Aly ^c   Ismail, Fatma ^a   Moustafa, Mamdouh ^d   Khalil, Said ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b European Egyptian Company for Pharmaceuticals   (Egypt)

^c KUWAIT UNIVERSITY   (Kuwait)

^d Drug Industries and Medical Appliances (ACDIMA)   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

3-PROPANEDIOL; ACTIVE INGREDIENTS; ACUTE PAINS; ARACHIDONIC ACIDS; AVERAGE COSTS; BODY TISSUES; CARBOXY METHYL CELLULOSE; CARBOXYLIC ACID DERIVATIVES; CONTROLLED RELEASE; CYCLO-OXYGENASE; DICLOFENAC; DISEASE STATE; DRUG RELEASE; EUDRAGIT; FLURBIPROFEN; GASTROINTESTINAL BLEEDING; INDOMETHACIN; KETOPROFEN; MATRIX FORMULATIONS; MATRIX TABLETS; METHYLCELLULOSE; NON IONICS; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; OPIOID ANALGESICS; PARENTERAL ADMINISTRATIONS; PATIENT COMPLIANCES; RELEASE PROFILES; SIDE EFFECTS; SODIUM CARBOXYMETHYL CELLULOSE; SUSTAINED RELEASE; THERAPEUTIC EFFECTS; TIME PERIODS; ZERO ORDERS;

ACIDS; AMINES; ANIMALS; BIOCHEMISTRY; CARBOXYLIC ACIDS; CARRIER CONCENTRATION; CELLULOSE; CELLULOSE DERIVATIVES; DERIVATIVES; DRUG INTERACTIONS; DRUG PRODUCTS; DYES; ENZYME ACTIVITY; METHANOL; ORGANIC ACIDS; PELLETIZING; POLYMERS; RAPID SOLIDIFICATION; SODIUM; TOLUENE;

DRUG THERAPY;

GALLIC ACID PROPYL ESTER; KETOROLAC TROMETAMOL; POLYMER;

ARTICLE; DRUG COATING; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PELLET; DRUG QUALITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; MICROENCAPSULATION; QUALITY CONTROL; SUSTAINED DRUG RELEASE;

ACIDS; AMINES; ANIMALS; BIOCHEMISTRY; CARBOXYLIC ACIDS; CHEMICAL CARRIERS; CONCENTRATION; DRUGS; DYES; ENZYMATIC ACTIVITY; ENZYMES; METHANOL; PELLETS; RELEASE;

EID: 59449095876     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. USP-DI (United States Pharmacopeial Convention Inc., 17th ed.,Rock- ville, MD, 1997),p. l788.
2. Physician's Desk Reference (Thomson PDR, 57th ed., Montvale, NJ, 2003), p. 2942.
3. M. Mori et al., "Prolongation of Antipyretic Action and Reduction of Gastric Ulcerogenicity in the Rat by Controlled-Release Granules of Bermoprofen, a New Nonsteroidal Anti-Inflammatory Drug," J. Pharm. Sci. 80, 876-880 (1991).
4. J. Rovensky and D. Micekova, "Six-Month Prospective Study to Monitor the Treatment of Rheumatic Diseases with Sustained-Release Flurbiprofen," Drug. Exp. Clin. Res. 26, 19-24 (2000).
5. T. Lee and J.R. Robinson, "Controlled-Release Drug-Delivery Systems," in Remington: The Science and Practice of Pharmacy (Lippincott Williams & Wilkins, 20th ed., Baltimore, MD, 2000), pp. 903-904.
6. L. Genc and N. Hegazy, "Sustained-Release Wax Matrix Formulations of Ketorolac Tromethamine with Compritol 888 ATO and HD 5 ATO," Acta Pharm. Turcia 42, 39-45 (2000).
7. D.M. Brahmankar, R.M. Karwa, and S.B. Jaiswal, "Cellulose Matrices for Controlled Release of Ketorolac Tromethamine," Indian Drugs 33, 120-123 (1996).
8. N. Vatsaraj, H. Zia, and T. Needham, "Formulation and Optimization of a Sustained-Release Tablet of Ketorolac Tromethamine," Drug Delivery 9, 153-159 (2002).
9. A.P. Rokhade et al., "Semi-Interpenetrating Polymer Network Microspheres of Gelatin and Sodium Carboxymethyl Cellulose for Controlled Release of Ketorolac Tromthamine," Carbohydrate Polymers 65, 243-252 (2006).
10. K. Ruckmani, M.S. Muneera, and R. Vijaya, "Eudragit Matrices for Sustained Release of Ketorolac Tromethamine and Kinetics of Release," Bollettino Chimico Farmaceutico 139, 205-208 (2000).
11. E.A. Hosny.A.A. Al-Helm,and E.M. Niazy,"In Vitro and In Vivo Evaluation of Commercial and Microcapsulated Sustained-Release Tablets Containing Diclofenac Sodium," Saudi Pharm. J. 6, 65-70 (1998).
12. M. Khan, J. Dib, and I.K. Reddy, "Statistical Optimization of Ketoprophen-Eudragit S-100 Coprecipitates to Obtain Controlled-Release Tablets," Drug Dev. Ind. Pharm. 22, 135-141 (1996).
13. C. Ho and G.C. Hwang, "Development of Extended-Release Solid Dispersions of Nonsteroidal Anti-Inflammatory Drugs with Aqueous Polymeric Dispersions: Optimization of Drug Release via a Curve-Fitting Technique," Pharm. Res. 9, 206-210 (1992).
14. J. Staniforth, "Powder Flow," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, 2nd ed., Edinburgh, Scotland, 2002), pp. 205-207.
15. USP26-NF21 (United States Pharmacopeial Convention Inc., Rockville, MD, 2002), pp. 978-980.
16. R.K. Chang and A.J. Shukla, "Polymethacrylates," in Handbook of Pharmaceutical Excipients, R.C. Rowe, P.J. Shesky, and P.J. Weller, Eds. (Pharmaceutical Press, 4th ed., London, England, 2002), pp. 462-468.
17. L. Genc, E. Guler, and N. Hegazy, "Film-Coated Enteric Tablet Formulation of Ketorolac Tromethamine," Drug Dev. Ind. Pharm. 23, 1007-1011 (1997).
18. T. Higuchi, "Mechanism of Sustained Action Medication. Theoretical Analysis of Rate Release of Solid Drugs Dispersed in Solid Matrices,"J. Pharm. Sci. 52, 1145-1149 (1963).
19. M. Donbrow, and S. Benita, "Release Kinetics of Sparingly Soluble Drugs from Ethyl Cellulose-Walled Microcapsules: Salicylamide Microcapsules,"J. Pharm. Pharmacol. 34, 547-551 (1982).
20. Z. Qiu et al., "Effect of Milling and Compression on the Solid-State Maillard Reaction," J. Pharm. Sci. 94, 2568-2580 (2005).
21. 21.R.C. George et al, "Investigation into the Yellowing on Aging of Sabril Tablet Cores," Drug Dev. Ind. Pharm. 20, 3023-3032 (1994).